FrancophonIA/ELRC3.0 huggingface dataset:
English: MabCampath is used to treat patients with B-cell chronic lymphocytic leukaemia (B-CLL), a cancer of a type of white blood cell called B lymphocytes.
Estonian: MabCampathit kasutatakse B-raku kroonilise lümfotsütaarse leukeemia (B-CLL) raviks, mis on Blümfotsüütide (teatud valgelibled) vähk.
English: How does MabCampath work?
Estonian: Kuidas MabCampath toimib?
English: It compared a 12-week course of MabCampath with a year-long course of chlorambucil (another anticancer medicine).
Estonian: Uuringus võrreldi MabCampathi 12-nädalast ravikuuri teise vähiravimi kloorambutsiili aastaste ravikuuridega.
English: Similar results were seen in the other two studies of
Estonian: Sarnased tulemused olid ka ülejäänud kahes varem ravitud patsientide uuringus.
English: MabCampath should not be used in people who may be hypersensitive (allergic) to alemtuzumab, mouse proteins, or any of the other ingredients.
Estonian: MabCampathit ei tohi kasutada patsiendid, kes võivad olla alemtusumabi, hiire valkude või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: MabCampath is a concentrate that is made up into a solution for infusion (drip into a vein).
Estonian: MabCampath on kontsentraat, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
English: Patients should be given steroids, an antihistamine and a painkiller before the first dose and before any increase in dose.
Estonian: Enne esimest annust ja iga kord enne annuse suurendamist tuleb patsientidele anda steroide, antihistamiini ja valuvaigistit.
English: Alemtuzumab has been designed to attach to a glycoprotein (a protein that is coated with sugar molecules) called CD52 that is found on the surface of lymphocytes.
Estonian: Alemtusumab seob CD52glükoproteiini (suhkrumolekulidega kaetud valk), mida leidub lümfotsüütide pinnal.
English: What is the risk associated with MabCampath?
Estonian: Mis riskid MabCampathiga kaasnevad?
English: MabCampath is used in patients for whom treatment combinations including fludarabine (another medicine used in leukaemia) are not appropriate.
Estonian: MabCampathit kasutatakse patsientidel, kellel fludarabiini (samuti leukeemiaravim) sisaldavaid kombinatsioonravimeid ei saa kasutada.
English: A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) that is found in certain cells in the body.
Estonian: MabCampathi toimeaine alemtusumab on monoklonaalne antikeha (teatud valk), mis tunneb ära teatud antigeeni (organismi teatud rakkudel leiduva spetsiifilise struktuuri) ja seondub sellega.
English: MabCampath treatment should be supervised by a doctor experienced in the use of cancer treatments.
Estonian: Ravi MabCampathiga peab toimuma vähiravi kogemusega arsti järelevalve all.
English: For the full list of all side effects reported with MabCampath,
Estonian: MabCampathi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Patients should be monitored during treatment to see how they respond, but also to check their blood levels of platelets (components that help the blood to clot) and neutrophils (a type of white blood cell that fights infection): if these are too low the treatment should be interrupted or stopped.
Estonian: Patsiente tuleb ravi ajal jälgida, et määrata kindlaks ravivastus ja kontrollida trombotsüütide (vereliistakud, hüübimist soodustavad vererakud) ja neutrofiilide (infektsiooniga võitlevad valgelibled)
English: In CLL, too many lymphocytes are produced.
Estonian: Kroonilise lümfotsüütleukeemia korral tekib lümfotsüüte liiga palju.
English: Therefore, the Committee concluded that MabCampath's benefits are greater than its risks for the treatment of patients with B-CLL for whom fludarabine combination chemotherapy is not appropriate.
Estonian: Komitee järeldas, et MabCampathi kasulikkus B-rakulise kroonilise lümfotsüütleukeemiaga patsientide ravimisel, kellel fludarabiini sisaldavaid kombinatsioonravimeid ei saa kasutada, on suurem kui sellega kaasnevad riskid.
English: What benefit has MabCampath shown during the studies?
Estonian: Milles seisneb uuringute põhjal MabCampathi kasulikkus?
English: See the summary of product characteristics (also part of the EPAR) for full details.
Estonian: Üksikasjalik teave on ravimi omaduste kokkuvõttes, mis on samuti Euroopa avaliku hindamisaruande osa.
English: 90 (3 x 30) capsules
Estonian: 90 (3 x 30) kapslit
English: Imfinzi (durvalumab)
Estonian: Imfinzi (durvalumaab)
English: Further information on Imfinzi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Imfinzi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Imfinzi?
Estonian: Mis meetmed võetakse, et tagada Imfinzi ohutu ja efektiivne kasutamine?
English: Imfinzi (durvalumab) EMA/521637/2018
Estonian: Imfinzi (durvalumaab) EMA/521637/2018
English: Treatment should continue for as long as the patient benefits from it or for up to 1 year.
Estonian: Ravi tuleb jätkata, kuni see on patsiendile kasulik või 1 aasta möödumiseni.
English: Other information about Imfinzi
Estonian: Muu teave Imfinzi kohta
English: The dose is calculated based on the patient's body weight.
Estonian: Annus arvutatakse patsiendi kehakaalu järgi.
English: The European Medicines Agency therefore decided that Imfinzi's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Imfinzi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: As for all medicines, data on the use of Imfinzi are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Imfinzi kasutamise kohta pidevat järelevalvet.
English: What is Imfinzi and what is it used for?
Estonian: Mis on Imfinzi ja milleks seda kasutatakse?
English: For more information about using Imfinzi, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Imfinzi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: By attaching to PDL1 and blocking its effects, Imfinzi increases the ability of the immune system to attack the cancer cells and thereby slow down the progression of the disease.
Estonian: PD-L1-ga seondudes ja selle toimet blokeerides tugevdab Imfinzi immuunsüsteemi võimet rünnata vähirakke ja seega aeglustada haiguse süvenemist.
English: Side effects reported with Imfinzi are carefully evaluated and any necessary action taken to protect patients.
Estonian: Imfinzi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: The use of Imfinzi is restricted to patients whose tumours produce PD-L1, since a clear benefit was only shown in this group of patients.
Estonian: Imfinzi on näidustatud üksnes patsientidele, kelle kasvajates tekib valku PD-L1, sest selge kasulik toime tõendati üksnes selles patsiendirühmas.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Imfinzi have been included in the summary of product characteristics and the package leaflet.
Estonian: Imfinzi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Imfinzi is given as an infusion (drip) into a vein every 2 weeks.
Estonian: Imfinzit manustatakse veeniinfusioonina iga 2 nädala järel.
English: PD-L1 acts to switch off immune cells that would otherwise attack the cancer cells.
Estonian: PD-L1 lülitab välja selliste immuunrakkude aktiivsuse, mis muidu ründaksid vähirakke.
English: Side effects with Imfinzi were considered manageable, and its safety profile acceptable and in line with that of similar medicines.
Estonian: Imfinzi kõrvalnähte peeti hallatavateks ning selle ohutusprofiili vastuvõetavaks ja sarnaste ravimite ohutusprofiilidega võrreldavaks.
English: The most common side effects with Imfinzi (which may affect more than 1 in 5 people) are cough, nose and throat infections, and rash.
Estonian: Imfinzi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 5st) on köha, nina-neelu infektsioonid ja lööve.
English: For the full list of side effects and restrictions of Imfinzi, see the package leaflet.
Estonian: Imfinzi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: What are the risks associated with Imfinzi?
Estonian: Mis riskid Imfinziga kaasnevad?
English: Preliminary results also indicated that patients given Imfinzi lived longer overall, compared with patients on placebo, though longer monitoring would be needed to confirm the extent of the benefit.
Estonian: Esialgsetest tulemustest nähtus samuti, et Imfinzit kasutanud patsientide üldine elumus oli pikem kui platseebot kasutanud patsientidel, ehkki kasulikkuse kestuse tõendamiseks on vaja pikemat jälgimisperioodi.
English: The most common serious side effect (which may affect up to 1 in 10 people) is pneumonia (infection of the lungs).
Estonian: Kõige sagedam raske kõrvalnäht (võib esineda kuni 1 patsiendil 10st) on kopsupõletik.
English: Imfinzi is used in adult patients with advanced cancer that cannot be removed by surgery but is not getting worse after treatment with radiation and platinum-based chemotherapy (medicines to treat cancer).
Estonian: Imfinzit kasutatakse kaugelearenenud vähiga täiskasvanud patsientidel, kui vähki ei ole võimalik eemaldada kirurgiliselt, kuid haigus ei ole pärast kiiritusravi ja plaatinapõhist keemiaravi (vähiravimid) süvenenud.
English: Imfinzi is a medicine used to treat a type of lung cancer called non-small cell lung cancer (NSCLC).
Estonian: Imfinzi on ravim, mida kasutatakse teatud tüüpi kopsuvähi, mitteväikerakk-kopsuvähi raviks.
English: Imfinzi can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in treating cancer.
Estonian: Ravi peab alustama ja jälgima vähiravis kogenud arst.
English: The active substance in Imfinzi, durvalumab, is a monoclonal antibody, a type of protein designed to recognise and attach to a protein called ‘programmed death-ligand 1' (PD-L1), which is present on the surface of many cancer cells.
Estonian: Imfinzi toimeaine durvalumaab on monoklonaalne antikeha (teatud valk), mis tunneb ära paljude vähirakkude pinnal oleva valgu PD-L1 (programmeeritud rakusurm-1) ja seondub sellega.
English: How does Imfinzi work?
Estonian: Kuidas Imfinzi toimib?
English: What benefits of Imfinzi have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Imfinzi kasulikkus?
English: Imfinzi contains the active substance durvalumab.
Estonian: Imfinzi sisaldab toimeainena durvalumaabi.
English: Treatment may be paused or stopped permanently if the patient experiences severe side effects.
Estonian: Kui patsiendil tekib raskeid kõrvalnähte, võib ravi katkestada või püsivalt lõpetada.
English: Imfinzi is used specifically when the tumour produces a protein known as PD-L1.
Estonian: Imfinzit kasutatakse siis, kui kasvajas tekib valku PD-L1.
English: How is Imfinzi used?
Estonian: Kuidas Imfinzit kasutatakse?
English: An overview of Imfinzi and why it is authorised in the EU
Estonian: Ülevaade ravimist Imfinzi ja ELis müügiloa väljastamise põhjendus
English: Imfinzi was shown to improve the length of time patients with advanced NSCLC lived without their disease getting worse, and this was considered important for these patients, who have few treatment options.
Estonian: Imfinzi suurendas kaugelearenenud mitteväikerakk-kopsuvähiga patsientide progresseerumiseta elumust ning seda peeti taolise väheste ravivalikutega patsiendirühma puhul oluliseks.
English: In one main study of 713 patients, patients given Imfinzi lived on average for around 17 months without their disease getting worse, compared with 6 months for those given placebo.
Estonian: progresseerumiseta elumus Imfinzit kasutanud patsientidel ligikaudu 17 kuud ja platseebot kasutanud patsientidel 6 kuud.
English: Imfinzi has been shown to be more effective than placebo (a dummy treatment) at prolonging the time patients with advanced non-small cell lung cancer lived without their disease getting worse.
Estonian: On tõendatud, et Imfinzi on kaugelearenenud mitteväikerakk-kopsuvähiga patsientide progresseerumiseta elumuse (kui kaua patsiendid elavad ilma haiguse süvenemiseta) pikendamisel efektiivsem kui platseebo (näiv ravim).
English: The safety of the medicine is in line with other similar medicines.
Estonian: Ravimi ohutus vastab muude sarnaste ravimite ohutusele.
English: Further information on Inbrija can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Inbrija.
Estonian: Lisateave Inbrija kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Inbrija.
English: What measures are being taken to ensure the safe and effective use of Inbrija?
Estonian: Mis meetmed võetakse, et tagada Inbrija ohutu ja efektiivne kasutamine?
English: As for all medicines, data on the use of Inbrija are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Inbrija kasutamise kohta pidevat järelevalvet.
English: The European Medicines Agency therefore decided that Inbrija's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Inbrija kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Other information about Inbrija
Estonian: Muu teave Inbrija kohta
English: This overview was last updated in 09-2019.
Estonian: Kokkuvõtte viimane uuendus: 08.2019
English: The recommended dose is 2 capsules in each ‘off' period up to a maximum of 10 capsules per day.
Estonian: Soovitatav annus on 2 kapslit igal liikumisraskustega perioodil, kuni maksimaalselt 10 kapslit ööpäevas.
English: What is Inbrija and what is it used for?
Estonian: Mis on Inbrija ja milleks seda kasutatakse?
English: Why is Inbrija authorised in the EU?
Estonian: Miks Inbrija ELis heaks kiideti?
English: For more information about using Inbrija, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Inbrija kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Inbrija have been included in the summary of product characteristics and the package leaflet.
Estonian: Inbrija ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Side effects reported with Inbrija are carefully evaluated and any necessary action taken to protect patients.
Estonian: Inbrija kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: The first study involved 226 patients who had 12 weeks of standard treatment with levodopa and a dopa-decarboxylase inhibitor.
Estonian: Esimeses uuringus osales 226 patsienti, kes said 12 nädalat levodopa ja dopa-dekarboksülaasi inhibiitori standardravi.
English: Because it is inhaled, Inbrija provides rapid relief of symptoms, which improves patients' quality of life.
Estonian: Et Inbrija on inhaleeritav, leevendab see sümptomeid kiiresti, mis parandab patsientide elukvaliteeti.
English: What are the risks associated with Inbrija?
Estonian: Mis riskid Inebrijaga kaasnevad?
English: Of patients treated with Inbrija, 71% reported that their symptoms were improved, compared with 46% of patients on placebo.
Estonian: Sümptomite vähenemisest teatas 71% Inbrijaga ravitud ja 46% platseeborühma patsientidest.
English: Effects were measured using a standard symptom scale known as the unified Parkinson's disease rating scale, UPDRS, part III.
Estonian: Mõju mõõdeti sümptomite standardskaalal (ühtlustatud Parkinsoni tõve hindamisskaala, UPDRS, III osa).
English: How is Inbrija used?
Estonian: Kuidas Inbrijat kasutatakse?
English: Inbrija contains levodopa which converts into dopamine in the brain and helps to restore dopamine levels, thereby improving the symptoms of the condition.
Estonian: Inbrija sisaldab levodopat, mis muundub ajus dopamiiniks ja aitab taastada dopamiinisisalduse, leevendades haigusseisundi sümptomeid.
English: In the second study involving 77 patients who had 4 weeks of standard treatment, patients who took Inbrija during ‘off' periods had an average improvement of 10 points on the scale 10 to 60 minutes later, compared with 3 points for patients taking placebo.
Estonian: Teises uuringus, kus osales 77 patsienti, kes said 4 nädalat standardravi, paranes 10-60 minuti pärast nende patsientide seisund, kes said liikumisraskustega perioodil Inbrijat, keskmiselt 10 punkti ning platseeborühma patsientide seisund 3 punkti.
English: It must also not be used in patients taking medicines known as non-selective monoamine oxidase (MAO) inhibitors or in patients with a history of neuroleptic malignant syndrome or rhabdomyolysis.
Estonian: Samuti ei tohi seda kasutada monoamiini oksüdaasi (MAO) mitteselektiivseid inhibiitoreid võtvad patsiendid ega pahaloomulise neuroleptosündroomi või rabdomüolüüsi anamneesiga patsiendid.
English: Two main studies have shown that Inbrija is effective at improving patients' symptoms during ‘off' periods.
Estonian: Kahe põhiuuringu kohaselt on Inbrija efektiivne patsientide sümptomite leevendamisel liikumisraskustega perioodidel.
English: The most common side effect with Inbrija is cough (which may affect more than 1 in 10 people).
Estonian: Inbrija kõige sagedam kõrvalnäht (võib esineda enam kui 1 patsiendil 10st) on köha.
English: Inbrija contains the active substance levodopa.
Estonian: Inbrija sisaldab toimeainena levodopat.
English: In patients with Parkinson's disease, the cells in the brain that produce dopamine, a neurotransmitter important for controlling movement, begin to die and the amount of dopamine in the brain decreases.
Estonian: Parkinsoni tõvega patsiendil hakkavad liigutuste juhtimiseks vajalikku neurotransmitterit dopamiini tootvad ajurakud hävima ja dopamiini kogus ajus väheneb.
English: What benefits of Inbrija have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Inbrija kasulikkus?
English: Inbrija is a medicine used to treat adults with Parkinson's disease (a progressive brain disease that causes shaking and muscle stiffness and slows movement).
Estonian: Inbrija on ravim, mida kasutatakse Parkinsoni tõvega (progresseeruv ajuhäire, mis põhjustab värisemist ja lihasjäikust ning aeglustab liigutusi) täiskasvanute raviks.
English: How does Inbrija work?
Estonian: Kuidas Inbrija toimib?
English: Medicines containing levodopa and a dopa-decarboxylase inhibitor have shown side effects of symptoms like neuroleptic malignant syndrome (a nervous disorder) and rhabdomyolysis (breakdown of muscle fibres).
Estonian: Levodopat ja dopa-dekarboksülaasi inhibiitorit sisaldavate ravimite kasutamisel on täheldatud selliseid kõrvalnähte nagu pahaloomuline neuroleptosündroom (närvisüsteemi häire) ja rabdomüolüüs (lihaskiudude lagunemine).
English: Other common side effects, which may affect up to 1 in 10 people, are falls, upper respiratory tract infection (nose and throat infection), dyskinesia (difficulty controlling movement) and discoloured sputum (phlegm).
Estonian: Muud sagedamad kõrvalnähud (võivad esineda kuni 1 patsiendil 10st) on kukkumine, ülemiste hingamisteede infektsioon (nina-neelupõletik), düskineesia (tahtmatud liigutused) ja röga värvimuutus.
English: In this study, patients who took Inbrija during their ‘off' periods had an average improvement of 10 points on the scale 30 minutes later, compared with 6 points for patients taking placebo (a dummy treatment).
Estonian: Selles uuringus paranes 30 minuti pärast nende patsientide seisund, kes said liikumisraskustega perioodil Inbrijat, keskmiselt 10 punkti ning platseeborühma (näiv ravim) patsientide seisund 6 punkti.
English: An overview of Inbrija and why it is authorised in the EU
Estonian: Ülevaade ravimist Inbrija ja ELis müügiloa väljastamise põhjendus
English: Inbrija must not be used in patients with narrow angle glaucoma (an eye disorder) or pheochromocytoma (a tumour of the adrenal glands).
Estonian: Inbrijat ei tohi kasutada kitsa nurga glaukoomiga (silmakahjustus) ega feokromotsütoomiga (neerupealiste kasvaja) patsiendid.
English: Inbrija should be inhaled using the Inbrija inhaler device when the patient recognises the symptoms of an ‘off' period.
Estonian: Patsient peab inhaleerima Inbrijat vastava inhalaatoriga, kui ta täheldab liikumisraskustega perioodi sümptomeid.
English: Inbrija is used to treat symptoms during ‘off' periods (times when the patient has more difficulty moving about) that occur while the patient is taking their usual treatment of a combination of levodopa and an inhibitor of dopa-decarboxylase.
Estonian: Inbrijat kasutatakse sümptomite raviks liikumisraskustega perioodidel (nn off-perioodid), mis esinevad tavapärase ravi, st levodopa ja dopa-dekarboksülaasi inhibiitori kombinatsiooni kasutamise ajal.
English: Inbrija is available as capsules containing a powder for inhalation and can only be obtained with a prescription.
Estonian: Inbrija on retseptiravim ja seda turustatakse inhalatsioonipulbri kapslitena.
English: Studies show that Inbrija is effective at reducing symptoms during ‘off' periods in patients with Parkinson's disease on levodopa/dopa-decarboxylase-inhibitor treatment.
Estonian: Uuringute kohaselt on Inbrija efektiivne levodopa / dopa-dekarboksülaasi inhibiitori ravi saavate Parkinsoni tõvega patsientide sümptomite leevendamisel liikumisraskustega perioodidel.
English: Because Inbrija is inhaled, it can supply extra levodopa (and hence dopamine) quickly when needed during an ‘off' period.
Estonian: Et Inbrijat inhaleeritakse, varustab see patsiente liikumisraskustega perioodil vajaduse korral kiiresti levodopa (st dopamiini) lisaannusega.
English: Allergic oedema (swelling) and gastrointestinal haemorrhage (bleeding in the gut) have been reported for other medicines containing levodopa.
Estonian: Muude levodopat sisaldavate ravimite kasutamisel on teatatud allergilisest ödeemist (turse) ja sooleverejooksust.
English: (see section 4.4.)
Estonian: (Vt lõik 4.4.)
English: The frequency of this side effect is not known (cannot be estimated from the available data).
Estonian: Selle kõrvaltoime esinemissagedus on teadmata (ei saa hinnata olemasolevate andmete alusel).
English: If you had these symptoms prior to treatment with cladribine, tell your doctor about any change in these symptoms.
Estonian: Kui teil esines neid sümptomeid juba enne kladribiinravi, teatage arstile nende sümptomite mis tahes muutustest.
English: Adopted at the 25-29 September 2017 PRAC
Estonian: Vastu võetud ravimiohutuse riskihindamise komitee 25.-29. septembri 2017 koosolekul
English: Some of these reactions with <product name> have resulted in recurrent symptoms and required a longer period of observation and treatment.
Estonian: Mõni neist reaktsioonidest ravimile <ravimi nimetus> on põhjustanud taastekkivaid sümptomeid ning vajanud pikemat jälgimisja raviperioodi.
English: Frequency ‘Not known': Jarisch-Herxheimer reaction (see section 4.4)
Estonian: Esinemissagedus „teadmata“: Jarischi-Herxheimeri reaktsioon (vt lõik 4.4)
English: Medicinal products concerned: cladribine-containing products authorised for oncology indications.
Estonian: Asjaomased ravimid: kladribiini sisaldavad ravimid, mis on heaks kiidetud kasutamiseks onkoloogilistel näidustustel.
English: Possible side effects [The following adverse drug reaction should be added with a frequency very rare (may affect up to 1 in 10,000 people)]
Estonian: Võimalikud kõrvaltoimed [Järgmised ravimite kõrvaltoimed peab lisama esinemissagedusega „väga harv“ (võivad esineda kuni 1 patsiendil 10 000st)]
English: • If you are taking or will be taking paracetamol
Estonian: • Kui te kasutate või hakkate kasutama paratsetamooli.
English: Package leaflet 4.
Estonian: Pakendi infoleht 4.